MS/Neuroimmunology
Clinical Research
If you think you may qualify for one of these studies, please contact Neurology Research Partners at (303) 724-4644 or NeurologyResearchPartners@CUAnschutz.edu
| COMIRB # | Title | Principal Investigator | Eligibility and Information | Advertisement |
|---|---|---|---|---|
20-1569 | A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients with Relapsing-Remitting Multiple Sclerosis | |||
20-0705 | A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients with Relapsing Multiple Sclerosis Transitioning from Dimethyl Fumarate or Fingolimod Therapy (ARTIOS) | n/a | ||
19-1621 | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | |||
| 19-2420 | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (Rpc-1063) | Amanda Piquet, MD | Clinical Trials | n/a |
20-2135 | A single-arm, prospective, multi-center, study to explore maintained efficacy with ofatumumab therapy in patients with relapsing Multiple Sclerosis who discontinue intravenously delivered anti-CD20 monoclonal antibody (aCD20 mAb) therapy (OLIKOS) | n/a | ||
20-0454 | A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis | n/a | ||
19-2525 | Lipoic Acid for Treatment of Progressive Multiple Sclerosis (LAPMS) | N/A | ||
21-3126 | The Evaluation Of Immune Responses To Sars-Cov-2 mRNA Vaccines In Multiple Sclerosis Patients On Ocrelizumab | |||
18-1633 | Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS) | N/A | ||
17-1884 | Risk Factors in Early Multiple Sclerosis (RISE-MS) | |||
19-0393 | Detection and Risk in Early MS (DREAMS) | N/A | ||
19-1600 | An Observational Study Of Ocrelizumab Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies (VERISMO) | N/A | ||
20-1000 | Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS) | N/A | ||
16-0156 | Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple Sclerosis (NAPPREMS) | N/A | ||
20-2153 | Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions for Ocrelizumab Users: Measuring Patient Experiences and Safety Outcomes | |||
20-0695 | Low Load Resistance Training Using Blood Flow Restriction for People with Multiple Sclerosis with Marked Mobility Restriction | |||
18-0179 | Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery | |||
20-1527 | Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People with Multiple Sclerosis | |||
12-0968 | Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders | n/a | ||
09-0952 | Rocky Mountain MS Center Tissue Bank | n/a |